Scisparc Announces the Full Exercise of Pre-Funded Warrants

The pre-funded warrants were issued as part of the $10 million private placement from June 2022

TEL AVIV, Israel, Aug. 19, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the full exercise of 3,211,100 pre-funded warrants that were issued as part of a private placement financing for gross proceeds of $10 million, which closed on June 1, 2022.

The full exercise of the 3,211,100 pre-funded warrants, which were exercised at a nominal exercise price of $0.001 per share, has resulted in the issuance of 3,211,100 ordinary shares.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.

Investor Contact:
Tel: +972-3-6167055

The content is by GlobeNewswire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.

Source link